STADA Romania, the Romanian subsidiary of the German group STADA Arzneimittel AG, announces for 2022 a consolidated business value of more than RON 247 million, up 37% compared to 2021, when it generated business of RON 180.1 million. STADA Group operates on the Romanian market through STADA M&D (pharmaceutical sales operations) and STADA Hemofarm (pharmaceutical testing laboratory and quality auditing).
STADA M&D estimates business of RON 188.8 million in 2022, up 32% as compared to the previous year. The results are unaudited and represent, for the first time, cumulative reporting with sales of SC Walmark SRL, after the completion of the local takeover of the entity. Walmark was globally acquired by STADA Group at the end of 2019.